Skip to content
lifestyle.ucconnection.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vera Therapeutics
Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy
September 15, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026
Vera Therapeutics to Participate at Upcoming Investor Conferences
September 1, 2026
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 10, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 2, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
May 21, 2026
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
1
2
Next Page
→